COCP

Cocrystal Pharma Inc

Add to Watchlist

Advanced Chart

1.090

0(0.000%)1D

Line

Candle

YTD

High

1.130

Open

1.110

VWAP

1.09

Vol

63.09K

Mkt Cap

14.21M

Low

1.075

Amount

68.80K

EV/EBITDA(TTM)

Total Shares

10.17M

9.45M

EV/OCF(TTM)

P/S(TTM)

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.200

-13.04%

-0.175

-45.31%

-0.215

-56.12%

Estimates Revision

The market is revising No Change the revenue expectations for Cocrystal Pharma, Inc. (COCP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -43.81%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.63%

In Past 3 Month

Stock Price

Go Down

-43.81%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast COCP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCP is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.090

Low

10.00

Averages

10.00

High

10.00

Current: 1.090

Low

10.00

Averages

10.00

High

10.00

H.C. Wainwright

Buy

downgrade

$7 -> $6

2025-06-21

Reason

H.C. Wainwright

Price Target

$7 -> $6

2025-06-21

downgrade

Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2025-01-22

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2025-01-22

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cocrystal Pharma Inc (COCP.O) is -1.39, compared to its 5-year average forward P/E of -2.81. For a more detailed relative valuation and DCF analysis to assess Cocrystal Pharma Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.81

Current PE

-1.39

Overvalued PE

0.29

Undervalued PE

-5.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.52

Undervalued EV/EBITDA

-0.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

17.85

Current PS

1.09

Overvalued PS

42.65

Undervalued PS

-6.96

Financials

Annual

Quarterly

FY2025Q2

N/A

Total Revenue

FY2025Q2

YoY :

-61.31%

-2.11M

Operating Profit

FY2025Q2

YoY :

-61.54%

-2.06M

Net Income after Tax

FY2025Q2

YoY :

-62.26%

-0.20

EPS - Diluted

FY2025Q2

YoY :

-41.74%

-2.16M

Free Cash Flow

FY2025Q2

N/A

Gross Profit Margin - %

FY2025Q2

N/A

FCF Margin - %

FY2025Q2

N/A

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

COCP News & Events

Events Timeline

2025-10-30 (ET)

2025-10-30

08:23:04

Cocrystal Pharma finalizes $1.03 million private placement deal

2025-10-27 (ET)

2025-10-27

08:18:08

Cocrystal Pharma awarded NIH SBIR grant to further develop influenza inhibitor initiative

2025-09-12 (ET)

2025-09-12

09:44:50

Cocrystal Pharma reveals direct offering of up to $13 million.

News

1.0

10-02Newsfilter

Cocrystal Pharma to Showcase at Noble Capital Markets Virtual Equity Conference for Emerging Growth Companies

8.5

09-12SeekingAlpha

Cocrystal Pharma reveals direct offering of up to $13 million.

9.0

05-29Newsfilter

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain